Vaccines - Angola

Angola

The Vaccines market in Angola is anticipated to achieve a revenue of US$78.93m in 2024.
This forecasted revenue is expected to exhibit an annual growth rate (CAGR 2024-2029) of -10.58%, leading to a market volume of US$45.12m by 2029.
When compared globally, United States is projected to generate the highest revenue of US$29,120.00m in 2024.
Angola's vaccine market is experiencing a surge in demand due to increased government focus on public health initiatives.

Key regions: Australia, Italy, France, South Korea, Brazil

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for vaccines in Angola has been steadily increasing in recent years.

Customer preferences: Angolan consumers are becoming more aware of the importance of preventative healthcare measures, including vaccinations. This is due in part to the efforts of the government and healthcare organizations to promote vaccination campaigns and education about the benefits of vaccines.

Trends in the market: The market for vaccines in Angola is expected to continue to grow as the government invests in expanding access to healthcare services and infrastructure. Additionally, there has been an increase in international aid and partnerships to support vaccination efforts in the country. The COVID-19 pandemic has also highlighted the importance of vaccines and may lead to increased demand for other vaccines in the future.

Local special circumstances: Despite the growing demand for vaccines, there are still challenges to expanding access in Angola. This includes a lack of healthcare infrastructure in some areas, as well as logistical challenges in distributing vaccines to remote regions. There is also a need for continued education and awareness campaigns to combat vaccine hesitancy and misinformation.

Underlying macroeconomic factors: Angola has experienced economic growth in recent years, which has led to increased investment in healthcare infrastructure and services. However, the country still faces challenges such as high levels of poverty and a lack of resources, which can impact access to healthcare and preventative measures like vaccines. The government has made healthcare a priority and is working to address these challenges through partnerships and investments in the sector.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.